Regimen for suppressing organ rejection
AssigneeVeloxis Pharmaceuticals, Inc.
InventorWilliam J. POLVINO
Life of this patent
Estimating the term…
Loading patent…
AssigneeVeloxis Pharmaceuticals, Inc.
InventorWilliam J. POLVINO
Estimating the term…
The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.
1-60. (canceled)
A method of suppressing early acute organ rejection in a transplant patient comprising orally administering a once-daily extended release tacrolimus dosage form at a dose of about 0.15 to about 0.20 mg/kg/day, wherein (i) the once-daily extended release tacrolimus dosage form provides a fluctuation of less than 100%, a swing less than 120%, or both, and (ii) the extended release dosage form releases at least 50% of the tacrolimus in the colon and/or the lower ileum.
Dependencies are inferred from the claim text.